Resveratrol for menopause: less pain, stronger bones, no cognitive benefit

A 2025 systematic review and meta-analysis published in Frontiers in Pharmacology found that resveratrol supplementation reduced pain and a marker of bone resorption in postmenopausal women. Across twelve other domains, including cognition, mood, metabolism, and sleep, the effect was null.

The analysis, led by Weidong Wu and colleagues at Heilongjiang University of Chinese Medicine, pooled data from 10 randomized controlled trials with 928 participants. It is the first to systematically evaluate resveratrol across the full range of outcomes that matter to postmenopausal women.

The findings narrow resveratrol’s credible benefit profile sharply. For more than a decade the polyphenol, found in red wine, grapes, and Japanese knotweed, has been sold as an anti-aging supplement. The marketing spans brain health, metabolic function, and menopause symptom relief. Most of those claims now lack trial support.

How the study was designed

The researchers searched seven databases (PubMed, Embase, the Cochrane Library, and four Chinese-language repositories) from inception through January 2025. No language restrictions. They identified 10 placebo-controlled RCTs conducted between 2012 and 2023 across Australia (six trials), the United States (two), New Zealand (one), and China (one). Doses ranged from 75 to 250 milligrams per day. Treatment periods ran from 14 weeks to 24 months.

The meta-analysis examined cognition and memory (12 separate outcome measures), mood (depression and overall mood scores), metabolic parameters (glucose, insulin, HOMA-IR, triglycerides, total cholesterol, LDL-C, HDL-C, and blood pressure), pain (three scales), sleep disturbance, menopausal symptoms, quality of life, and three bone metabolism markers.

Cochrane risk-of-bias scores ranged from 4 to 7 out of 7. Six studies scored the maximum 7. Nine of ten reported both allocation concealment and double-blinding. An Egger test found no significant publication bias (p = 0.301).

What resveratrol actually improved

Two outcomes reached statistical significance.

Pain was the clearest signal. Across three pain scales, resveratrol outperformed placebo. General pain scores dropped by a weighted mean difference of 2.84 points (95% CI: -5.63 to -0.05, p = 0.046). Pain measured on the visual analog scale fell by 7.59 points (95% CI: -12.91 to -2.26, p = 0.005). Present Pain Intensity scores dropped by 8.56 points (95% CI: -12.87 to -4.26, p < 0.001).

The authors point to resveratrol’s anti-inflammatory and antioxidant properties, documented in preclinical work, as the likely mechanism. They caution that the effect sizes are small and may not meet the threshold for a minimal clinically important difference.

The bone resorption marker CTX (C-terminal telopeptide of type I collagen) also fell. The weighted mean difference was 0.14 (95% CI: -0.20 to -0.07, p < 0.001). Lower CTX means less bone is being broken down. That is a directionally favorable signal for postmenopausal bone health. Two other bone markers, ALP and osteocalcin, did not change.

What did not change

The breadth of null findings is the story. Of roughly two dozen outcomes examined, only four reached significance. Everything else came back flat.

Cognition and memory returned null results across all 12 measures. Processing speed, reaction time, pattern recognition, delayed recall, working memory, sustained attention, cognitive flexibility. None showed a difference between resveratrol and placebo. Two measures came close but did not cross the threshold: the Flanker inhibitory control task (p = 0.079) and the Dimensional Change Card Sort (p = 0.052).

Mood was unaffected. Depression scores (WMD: -0.76, p = 0.338) and overall mood (WMD: 0.97, p = 0.666) did not shift.

Metabolic markers were flat. Glucose, insulin, HOMA-IR, triglycerides, total cholesterol, LDL-C, HDL-C. All near-zero mean differences. Confidence intervals spanned zero in every case. Blood pressure did not change.

Sleep disturbance, measured by the Pittsburgh Sleep Quality Index, was no better with resveratrol than placebo (WMD: -1.43, p = 0.490). Menopausal symptoms (psychological, somatic, urogenital) did not shift. SF-36 quality of life scores were unchanged (WMD: 1.25, p = 0.344).

Why the null results matter

Resveratrol’s reputation was built on a thin base. Cell-culture studies. Animal models. The French paradox story that turned red wine polyphenols into a health narrative. None of that early work was tested in postmenopausal women at scale.

From there, the market ran ahead of the evidence. Supplement brands layered on claims about brain aging, metabolic health, hormone balance. Women in midlife became the target audience. But the trials that would eventually test those claims simply had not been done yet.

This meta-analysis fills that gap. Ten trials. Nine hundred and twenty-eight women. The answer, across most outcomes, is that resveratrol did not separate from placebo.

The pain finding is the one exception worth taking seriously. Three different scales. Consistent direction. The mechanism (anti-inflammatory action) has a plausible biological basis. The catch is that the effect sizes are small. A 2.84-point drop on a general pain scale may not cross the threshold for what patients actually feel as improvement.

The CTX finding is mechanistically clean (less bone resorption is directionally good) but it is a surrogate marker. No fracture data. No long-term bone density outcomes. It is a signal, not an answer.

The study has weaknesses. Three of ten RCTs lacked adequate randomization detail. Heterogeneity was moderate to high for delayed recall (I-squared 62.8 percent) and diastolic blood pressure (I-squared 56.1 percent). With only 10 studies spread across two dozen outcomes, subgroup analyses were not possible. Doses, formulations, and treatment lengths varied enough that effects specific to one regimen could be washed out.

Then there is the bioavailability problem. Resveratrol is poorly absorbed. Most of an oral dose is metabolized before it reaches the brain. The trial durations, which topped out at 24 months, may simply have been too short for a compound that never reaches high plasma concentrations.

What this means

The evidence supports a narrow use case. Resveratrol at 75 to 250 milligrams per day may reduce pain and slow bone resorption in postmenopausal women, modestly. For someone with joint or musculoskeletal pain during menopause, it may be worth discussing with a doctor. Expectations should be calibrated to the small effect sizes seen in the trials.

For cognition, mood, sleep, hot flashes, metabolism, or quality of life, the trials found nothing. Women taking resveratrol for those purposes are betting on mechanisms that did not show up when actually tested.

The study was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Heilongjiang Province. The authors report no conflicts of interest. The review was prospectively registered with PROSPERO (CRD42024566807).

As with any supplement, consult a doctor before starting, particularly if taking other medications or if there is a history of hormone-sensitive conditions.

References

1. Wu W, Meng T, Jin F, et al. Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis. Frontiers in Pharmacology 16. 2025. https://doi.org/10.3389/fphar.2025.1588284
2. Li Q, Yang G, Xu H, et al. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complementary Medicine and Therapies 21(1):214. 2021. https://doi.org/10.1186/s12906-021-03381-4